Lorrain Daniel S. 4

What Happened Daniel S. Lorrain, Chief Scientific Officer of Contineum Therapeutics (CTNM), was granted stock option awards on 2026-01-30. The Form 4 reports two derivative grants: 160,000 option shares and 6,500 option shares, each reported at an acquisition price of $0.00 (transaction code A — award/grant). The combined award totals 166,500 option shares. The filing classifies these as derivative securities (options), not open-market purchases or sales.

Key Details

• Transaction date: 2026-01-30 (Form 4 filed same day).
• Grants: 160,000 options (F1) and 6,500 options (F2); acquisition price reported as $0.00 for each grant.
• Vesting: Options vest in equal monthly installments over 48 months, subject to continuous service.
• Footnotes: F1 = grant under the 2024 Equity Incentive Plan to the Reporting Person; F2 = grant under the Plan in connection with the Reporting Person’s spouse’s continuous service.
• Shares owned after transaction: Not disclosed in the provided filing excerpt.
• Timeliness: Filing appears timely (transaction date and period of report are the same).

Context These are option grants (derivative awards). Reporting of $0.00 at grant is common for option awards on Form 4 and does not indicate the exercise price or eventual value — exercise price and other award terms may be in the underlying award agreement or a separate filing. As routine equity compensation, grants reflect compensation/retention mechanics rather than an immediate market buy/sell; they only become economically meaningful when vested and exercised.